EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Metabolic bariatric surgery is associated with reduced adverse hepatic and extrahepatic outcomes, and lower all‐cause mortality, in patients with steatotic liver disease

Weronika Stupalkowska iD, Alexander Henney, Eric G Sheu, Uazman Alam, Daniel J Cuthbertson

Diabetes, Obesity and Metabolism · 2026-01 · 28 (1) · 174-185

DOI: 10.1111/dom.70173 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 30.09.2025. Verfasst von Weronika Stupalkowska und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK. Hauptthemen laut MEDLINE: Bariatric Surgery, Fatty Liver, Obesity, Morbid. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Metabolic bariatric surgery (MBS) improves histological endpoints in steatotic liver disease (SLD), but data on longer‐term clinical outcomes in this population are scarce. Here, we assessed the impact of MBS on hepatic and extrahepatic morbidity and mortality in individuals with SLD.

Methods

Patients with SLD, with/without a history of MBS (MBS/no‐MBS cohorts, respectively) between 01/01/2004 and 31/10/2019, were identified using the TriNetX platform. Cohorts were balanced with propensity score matching (PSM). Maximum follow‐up was set to 5 years. The primary outcome was a composite of major adverse liver outcomes (MALO): cirrhosis, decompensated cirrhosis, hepatocellular carcinoma, and liver transplant. Secondary outcomes included major cardiovascular (MACE) and kidney (MAKE) adverse events, obesity‐associated cancers, and all‐cause mortality (ACM). We performed sub‐group analyses according to sex, MBS type, and risk factors (BMI ≥50 kg/m 2 and type 2 diabetes (T2D)).

Results

We identified 15,262 and 540,031 patients (for the MBS and no‐MBS cohorts, respectively); 14,970 patients/cohort after PSM (mean age: 46.7 vs. 47.4; female: 74.3% vs. 75.7%; mean follow‐up, 4.1 years). MBS was associated with reduced HR of MALO (0.84, 95% CI 0.75–0.95), MACE (0.52, CI 0.47–0.57), MAKE (0.54, CI 0.41–0.72), obesity‐related cancers (0.58, CI 0.50–0.67), and ACM (0.49, 0.43–0.56). In subgroup analyses, MBS was associated with reduced HR of MALO, MACE, MAKE, obesity‐related cancers, and ACM in females, patients with T2D, BMI > 50 kg/m 2 and irrespective of surgery type.

Conclusion

In patients with SLD, MBS is associated with significant reductions in the rates of adverse hepatic and extrahepatic outcomes and all‐cause mortality over 4 years' follow‐up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bariatric SurgeryFatty LiverObesity, MorbidHumansFemaleMaleMiddle AgedAdultDiabetes Mellitus, Type 2Risk FactorsCause of DeathTreatment OutcomePropensity Score

Autor:innen und Institutionen

  • Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
  • Laboratory for Surgical and Metabolic Research, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Metabolism & Nutrition Research Group, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
  • Division of General and GI Surgery, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Liverpool Centre for Cardiovascular Sciences, University of Liverpool and Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
  • Centre for Biomechanics and Rehabilitation Technologies, Staffordshire University, Stoke-on-Trent, UK.

ORCID-Profile: Weronika Stupalkowska

Zitieren

APA

Stupalkowska, W., Henney, A., Sheu, E. G., Alam, U., & Cuthbertson, D. J. (2026). Metabolic bariatric surgery is associated with reduced adverse hepatic and extrahepatic outcomes, and lower all‐cause mortality, in patients with steatotic liver disease. Diabetes, Obesity and Metabolism, 28(1), 174-185. https://doi.org/10.1111/dom.70173

Vancouver

Stupalkowska W, Henney A, Sheu EG, Alam U, Cuthbertson DJ. Metabolic bariatric surgery is associated with reduced adverse hepatic and extrahepatic outcomes, and lower all‐cause mortality, in patients with steatotic liver disease. Diabetes, Obesity and Metabolism. 2026;28(1):174-185. doi:10.1111/dom.70173

BibTeX
@article{Stupalkowska2026,
  author = {Stupalkowska, Weronika and Henney, Alexander and Sheu, Eric G and Alam, Uazman and Cuthbertson, Daniel J},
  title = {Metabolic bariatric surgery is associated with reduced adverse hepatic and extrahepatic outcomes, and lower all‐cause mortality, in patients with steatotic liver disease},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {1},
  pages = {174--185},
  doi = {10.1111/dom.70173}
}
Kostenlos starten →